BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu DY, Yalçin H, Yalçin F, Zhao M, Sivalokanathan S, Valenta I, Tahari A, Pomper MG, Abraham TP, Schindler TH, Abraham MR. Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2018;121:1081-9. [PMID: 29678336 DOI: 10.1016/j.amjcard.2018.01.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Pelliccia F, Cecchi F, Olivotto I, Camici PG. Microvascular Dysfunction in Hypertrophic Cardiomyopathy. JCM 2022;11:6560. [DOI: 10.3390/jcm11216560] [Reference Citation Analysis]
2 Grozdic Milojevic I, Kozarevic N, Sobic‐saranovic D. Novel nuclear medical procedures in the detection of microvascular dysfunction. J of Clinical Ultrasound 2022;50:1143-1150. [DOI: 10.1002/jcu.23322] [Reference Citation Analysis]
3 Ruddy TD, Tavoosi A, Taqueti VR. Role of nuclear cardiology in diagnosis and risk stratification of coronary microvascular disease. J Nucl Cardiol . [DOI: 10.1007/s12350-022-03051-z] [Reference Citation Analysis]
4 Zhan J, Zhong L, Wu J. Assessment and Treatment for Coronary Microvascular Dysfunction by Contrast Enhanced Ultrasound. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.899099] [Reference Citation Analysis]
5 Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A, Gilliland Y, Lester SJ, Maldonado Y, Mohiddin S, Nieman K, Sperry BW, Woo A. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2022;35:533-69. [PMID: 35659037 DOI: 10.1016/j.echo.2022.03.012] [Reference Citation Analysis]
6 Kharche SR, Lemoine S, Tamasi T, Hur L, So A, McIntyre CW. Therapeutic Hypothermia Reduces Peritoneal Dialysis Induced Myocardial Blood Flow Heterogeneity and Arrhythmia. Front Med (Lausanne) 2021;8:700824. [PMID: 34395480 DOI: 10.3389/fmed.2021.700824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tonet E, Pompei G, Faragasso E, Cossu A, Pavasini R, Passarini G, Tebaldi M, Campo G. Coronary Microvascular Dysfunction: PET, CMR and CT Assessment. J Clin Med 2021;10:1848. [PMID: 33922841 DOI: 10.3390/jcm10091848] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
8 Bandera F, Baghdasaryan L, Mandoli GE, Cameli M. Multimodality imaging predictors of sudden cardiac death. Heart Fail Rev 2020;25:427-46. [PMID: 31792657 DOI: 10.1007/s10741-019-09893-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Lai AC, Bienstock SW, Sharma R, Skorecki K, Beerkens F, Samtani R, Coyle A, Kim T, Baber U, Camaj A, Power D, Fuster V, Goldman ME. A Personalized Approach to Chronic Kidney Disease and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2021;77:1470-9. [PMID: 33736830 DOI: 10.1016/j.jacc.2021.01.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
10 Rrapo Kaso E, Kramer CM. Multimodality Imaging for Hypertrophic Cardiomyopathy. Curr Treat Options Cardio Med 2020;22. [DOI: 10.1007/s11936-020-00827-9] [Reference Citation Analysis]
11 Liu L, Liu S, Shen L, Tu B, Hu Z, Hu F, Zheng L, Ding L, Fan X, Yao Y. Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy. Clin Cardiol 2020;43:1150-9. [PMID: 32810305 DOI: 10.1002/clc.23425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Schindler TH, Bateman TM, Berman DS, Chareonthaitawee P, De Blanche LE, Dilsizian V, Dorbala S, Gropler RJ, Shaw L, Soman P, Winchester DE, Verberne H, Ahuja S, Beanlands RS, Di Carli MF, Murthy VL, Ruddy TD, Schwartz RG. Appropriate Use Criteria for PET Myocardial Perfusion Imaging. J Nucl Med 2020;61:1221-65. [PMID: 32747510 DOI: 10.2967/jnumed.120.246280] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
13 Schindler TH, Brown DL, Sadhu JS. Adding clinical value with coronary flow assessment in hypertrophic obstructive cardiomyopathy. IJC Heart & Vasculature 2020;27:100512. [DOI: 10.1016/j.ijcha.2020.100512] [Reference Citation Analysis]
14 Ramchand J, Fava AM, Chetrit M, Desai MY. Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy. Heart 2020;106:793-801. [DOI: 10.1136/heartjnl-2019-315176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Lu DY, Ventoulis I, Liu H, Kudchadkar SM, Greenland GV, Yalcin H, Kontari E, Goyal S, Corona-Villalobos CP, Vakrou S, Zimmerman SL, Abraham TP, Abraham MR. Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy. Am Heart J 2020;219:58-69. [PMID: 31726421 DOI: 10.1016/j.ahj.2019.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
16 Magnusson P, Nordström J, Harms HJ, Lubberink M, Gadler F, Sörensen J, Mörner S. Positron emission tomography (15O-water, 11C-acetate, 11C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. Int J Cardiol Heart Vasc 2020;26:100452. [PMID: 32140548 DOI: 10.1016/j.ijcha.2019.100452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Liu Y, Afzal J, Vakrou S, Greenland GV, Talbot CC Jr, Hebl VB, Guan Y, Karmali R, Tardiff JC, Leinwand LA, Olgin JE, Das S, Fukunaga R, Abraham MR. Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy. Front Cardiovasc Med 2019;6:170. [PMID: 31921893 DOI: 10.3389/fcvm.2019.00170] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
18 Schindler TH, Dilsizian V. Coronary Microvascular Dysfunction: Clinical Considerations and Noninvasive Diagnosis. JACC Cardiovasc Imaging 2020;13:140-55. [PMID: 30982670 DOI: 10.1016/j.jcmg.2018.11.036] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
19 Sciagrà R. Microvascular Dysfunction in Hypertrophic Cardiomyopathy. Curr Cardiovasc Imaging Rep 2019;12. [DOI: 10.1007/s12410-019-9478-4] [Reference Citation Analysis]
20 Schindler TH. From Myocardial Blood Flow to Receptor Imaging with PET. Annals of Nuclear Cardiology 2019;5:131-140. [DOI: 10.17996/anc.19-00094] [Reference Citation Analysis]
21 Kay GN. Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy? J Nucl Cardiol 2019;26:1135-7. [PMID: 29761308 DOI: 10.1007/s12350-018-1299-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Bravo PE. Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy? J Nucl Cardiol 2019;26:1125-34. [DOI: 10.1007/s12350-018-1298-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]